Human Reproduction, Vol. 15, No. 11, 2333-2340,
November 2000
© 2000 European Society of Human Reproduction and Embryology
Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study
Research Institute for Endocrinology, Reproduction and Metabolism, IVF Center, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
Gonadotrophin-releasing hormone agonists (GnRHa) are routinely used in IVF programmes to prevent an unwanted LH surge and consequent ovulation. Despite its widespread use in IVF, a convincing dose recommendation for GnRHa in IVF does not exist. In our opinion, the lowest possible dose of GnRHa should be used. Thus, we performed a prospective, randomized, double-blind, placebo-controlled study to determine the minimal daily dose of triptorelin acetate needed to suppress a premature LH surge during IVF treatment in a long protocol. A total of 240 women (60 in each group) was randomized to either placebo or to one of three doses of triptorelin, i.e. 15, 50 or 100 µg daily. Ovarian stimulation was performed with two or three ampoules of FSH daily. A premature LH surge occurred in 23% of placebo-treated patients, but in none of the triptorelin acetate-treated patients. There were significantly more oocytes and embryos in the 50 and 100 µg triptorelin groups. There was no dose relationship in rates of either implantation, pregnancy, ongoing pregnancy, live birth or baby take-home. In this study we showed that daily administration of 15 µg triptorelin is sufficient to prevent a premature LH surge, and that 50 µg is equivalent to 100 µg in terms of IVF results.
Key words: dose reduction/IVF/LH surge/triptorelin
1 To whom correspondence should be addressed at: Department of Obstetrics and Gynaecology, Free University Hospital, IVF Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands. E-mail: cb.lambalk{at}azvu.nl
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. Jayaprakasan, B.K. Campbell, J.F. Hopkisson, J.S. Clewes, I.R. Johnson, and N.J. Raine-Fenning Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone Hum. Reprod., November 1, 2008; 23(11): 2577 - 2583. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Jayaprakasan, J.F. Hopkisson, B.K. Campbell, J. Clewes, I.R. Johnson, and N.J. Raine-Fenning Quantification of the effect of pituitary down-regulation on 3D ultrasound predictors of ovarian response Hum. Reprod., July 1, 2008; 23(7): 1538 - 1544. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. NyboeAndersen, P. Humaidan, G. Fried, J. Hausken, L. Antila, S. Bangsboll, P.E. Rasmussen, S. Lindenberg, H. E. Bredkjaer, H. Meinertz, et al. Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial Hum. Reprod., February 1, 2008; 23(2): 427 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A. Huirne, R. Homburg, and C.B. Lambalk Are GnRH antagonists comparable to agonists for use in IVF? Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Safdarian, F. S. Mohammadi, A. Alleyassin, M. Aghahosseini, A. Meysamie, and E. Rahimi Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916) Hum. Reprod., September 1, 2007; 22(9): 2449 - 2454. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Trew Comparing highly purified hMG and rFSH in patients undergoing IVF Hum. Reprod., June 1, 2007; 22(6): 1797 - 1798. [Full Text] [PDF] |
||||
![]() |
A. N. Andersen, P. Devroey, and J.-C. Arce Reply: Comparing highly purified hMG and rFSH in patients undergoing IVF Hum. Reprod., June 1, 2007; 22(6): 1798 - 1800. [Full Text] [PDF] |
||||
![]() |
C. B. Lambalk and R. Homburg GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution Hum. Reprod., October 1, 2006; 21(10): 2580 - 2582. [Full Text] [PDF] |
||||
![]() |
N. S. Macklon, R. L. Stouffer, L. C. Giudice, and B. C. J. M. Fauser The Science behind 25 Years of Ovarian Stimulation for in Vitro Fertilization Endocr. Rev., April 1, 2006; 27(2): 170 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
I.E. Messinis, D. Loutradis, E. Domali, C.P. Kotsovassilis, L. Papastergiopoulou, A. Kallitsaris, P. Drakakis, K. Dafopoulos, and S. Milingos Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment Hum. Reprod., November 1, 2005; 20(11): 3192 - 3197. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-C. Arce, A. Nyboe Andersen, and J. Collins Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: a mini-review Hum. Reprod., July 1, 2005; 20(7): 1757 - 1771. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A.F. Huirne, A. C.D. van Loenen, R. Schats, J. McDonnell, P. G.A. Hompes, J. Schoemaker, R. Homburg, and C. B. Lambalk Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy Hum. Reprod., February 1, 2005; 20(2): 359 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Yu Ng, C. Chi Wai Chan, O. S. Tang, W. Shu Biu Yeung, and P. Chung Ho Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation Hum. Reprod., December 1, 2004; 19(12): 2811 - 2815. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Dal Prato, A. Borini, G. Coticchio, M. Cattoli, and C. Flamigni Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study Hum. Reprod., October 1, 2004; 19(10): 2200 - 2205. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A.F. Huirne, A. C.D. van Loenen, R. Schats, J. McDonnell, P. G.A. Hompes, J. Schoemaker, R. Homburg, and C. B. Lambalk Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels Hum. Reprod., October 1, 2004; 19(10): 2206 - 2215. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Balasch, E. Vidal, J. Penarrubia, R. Casamitjana, F. Carmona, M. Creus, F. Fabregues, and J. A. Vanrell Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH Hum. Reprod., August 1, 2001; 16(8): 1636 - 1643. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.D. Prato, A. Borini, M.R. Trevisi, M.A. Bonu, E. Sereni, and C. Flamigni Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study Hum. Reprod., July 1, 2001; 16(7): 1409 - 1414. [Abstract] [Full Text] [PDF] |
||||

